MOLN

Oct 29, 4:01 AMMolecular Partners to cut workforce by up to ~44% as it sharpens focus on radiopharmaceuticals

Peers: CATX TLX JANX MGNX CLRB XNCR ZLAB IMTX ZYME LNTH

Index	-
Market Cap	134.47M
Enterprise Value	54.03M
Income	-64.55M
Sales	0.00M
Book/sh	1.89
Cash/sh	2.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	149
IPO	Jun 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.85
P/C	1.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.27
Current Ratio	7.27
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	-1.71
EPS next Y	-1.49
EPS next Q	-0.43
EPS this Y	18.39%
EPS next Y	13.41%
EPS next 5Y	9.82%
EPS past 3/5Y	- 5.73%
Sales past 3/5Y	- -
EPS Y/Y TTM	17.74%
Sales Y/Y TTM	-100.00%
EPS Q/Q	32.11%
Sales Q/Q	-
Earnings	Oct 29 BMO
EPS/Sales Surpr.	0.00% -

Insider Own	0.28%
Insider Trans	0.00%
Inst Own	9.38%
Inst Trans	0.04%
ROA	-51.65%
ROE	-62.49%
ROIC	-86.24%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.58%
SMA50	-12.70%
SMA200	-16.02%
Trades

Shs Outstand	38.31M
Shs Float	38.20M
Short Float	0.00%
Short Ratio	0.28
Short Interest	0.00M
52W High	5.36 -34.51%
52W Low	3.52 -0.28%
Volatility	3.79% 3.51%
ATR (14)	0.17
RSI (14)	39.59
Beta	1.17
Rel Volume	1.71
Avg Volume	2.04K
Volume	1,023

Perf Week	-4.36%
Perf Month	-10.23%
Perf Quarter	-14.81%
Perf Half Y	-17.22%
Perf YTD	-19.47%
Perf Year	-6.90%
Perf 3Y	-0.57%
Perf 5Y	-81.14%
Perf 10Y	-
Recom	1.33
Target Price	10.20
Prev Close	3.53
Price	3.51
Change %	-0.57%

Consensus

Strong Buy

Avg. Price Target

$10.20

Implied Upside

+190.6%

Analysts5incl. previous ratings

Rating Distribution2 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 27, 2026	Initiated	HH.C. Wainwright	Buy	$13	+270.4%
Aug 30, 2022	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform
Aug 29, 2022	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$30 → $8	+127.9%
May 25, 2022	Upgrade	CCredit Suisse	Underperform → Neutral
Apr 27, 2022	Downgrade	CCredit Suisse	Neutral → Underperform
Jul 13, 2021	Initiated	CCowen	Outperform	$50	+1,324.5%
Jul 12, 2021	Resumed	SSVB Leerink	Outperform	$36	+925.6%

Oct-29-26 02:00AM	Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy (GlobeNewswire)
Oct-22-26 01:00AM	Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 (GlobeNewswire)
Aug-25-26 01:00AM	Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study (GlobeNewswire)
Jul-16-26 01:00AM	Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma (GlobeNewswire)
Jul-15-26 01:00AM	Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference (GlobeNewswire)
01:00AM	Loading…
Jul-06-26 01:00AM	Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics (GlobeNewswire)
Jul-02-26 01:00AM	Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (GlobeNewswire)
May-30-26 08:00AM	Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 (GlobeNewswire)
May-26-26 04:00PM	Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit (GlobeNewswire)
May-13-26 09:03PM	Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ... (GuruFocus.com)
May-12-26 04:00PM	Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 (GlobeNewswire)
May-04-26 01:00AM	Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences (GlobeNewswire)
May-01-26 07:00AM	Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling (GlobeNewswire)
Apr-19-26 12:00PM	Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 (GlobeNewswire)
Apr-14-26 04:00PM	Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting (GlobeNewswire)
09:00AM	Loading…
Mar-23-26 09:00AM	Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors (GlobeNewswire)
Mar-19-26 02:00AM	Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes (GlobeNewswire)
Mar-17-26 04:30PM	Molecular Partners to Hold Three Poster Presentations at AACR 2026 (GlobeNewswire)
Mar-12-26 04:00PM	Molecular Partners Reports Highlights and Financial Results for Full Year 2025 (GlobeNewswire) -10.40%
Mar-04-26 08:29AM	Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? (Zacks)
Feb-26-26 01:00AM	Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics (GlobeNewswire)
01:00AM	Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results (GlobeNewswire)
Feb-02-26 03:30PM	Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready (MarketBeat) +7.53%
01:00AM	Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 (GlobeNewswire)
Jan-11-26 03:00PM	Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 01:00AM	Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 07:00AM	Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics (GlobeNewswire)
Dec-07-25 07:00AM	Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting (GlobeNewswire)
Nov-12-25 01:00AM	Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action (GlobeNewswire)
Nov-03-25 01:00AM	Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting (GlobeNewswire) +12.42%
01:00AM	Loading…
01:00AM	Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 (GlobeNewswire)
Oct-30-25 04:00PM	Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 (GlobeNewswire)
Aug-25-25 04:00PM	Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 (GlobeNewswire) +14.85% -7.71%
Aug-21-25 01:00AM	Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics (GlobeNewswire)
Jun-22-25 04:00PM	Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 (GlobeNewswire)
Jun-11-25 04:00PM	Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 (GlobeNewswire) +8.03%
Jun-10-25 01:00AM	Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway (GlobeNewswire)
May-19-25 01:00AM	Molecular Partners to Present at Upcoming Investor Conferences (GlobeNewswire)
May-15-25 04:00PM	Molecular Partners Reports Financial Results and Highlights from Q1 2025 (GlobeNewswire)
Apr-25-25 04:00PM	Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 (GlobeNewswire)
Apr-16-25 12:00PM	Molecular Partners Announces all Board Proposals Approved at Annual General Meeting (GlobeNewswire) -8.70%
Apr-03-25 09:55AM	Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher (Zacks)
Mar-25-25 04:00PM	Molecular Partners to hold three poster presentations at AACR 2025 (GlobeNewswire) +10.70%
12:00PM	Molecular Partners Publishes Invitation to Annual General Meeting 2025 (GlobeNewswire)
Mar-06-25 04:00PM	Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 (GlobeNewswire)
Feb-28-25 01:00AM	Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call (GlobeNewswire)
Jan-12-25 01:00PM	Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
01:00PM	Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer (GlobeNewswire)
Dec-17-24 04:00PM	Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January (GlobeNewswire)
Dec-08-24 12:00PM	Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 (GlobeNewswire)
Nov-07-24 04:00PM	Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 (GlobeNewswire)
Nov-05-24 04:00PM	Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.06% +8.52%
Oct-31-24 04:00PM	Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going (GlobeNewswire) -12.85% +14.18%
Oct-25-24 01:00AM	Molecular Partners Announces Pricing of $20 Million Underwritten Offering (GlobeNewswire) +7.81%
Oct-23-24 09:29AM	Molecular Partners Expands Radio-DARPin Collaboration (TipRanks) -13.71%
Oct-22-24 01:00AM	Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics (GlobeNewswire)
01:00AM	Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 (GlobeNewswire)
Oct-04-24 01:00AM	Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting (GlobeNewswire) +9.61%
Sep-27-24 01:00AM	Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 (GlobeNewswire) +8.10%
Aug-26-24 04:00PM	Molecular Partners Reports H1 2024 Corporate Highlights and Financials (GlobeNewswire) +11.79%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -25.10%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +38.32%
Jun-17-24 01:00AM	Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit (GlobeNewswire) +7.68%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +13.78%
01:00AM	Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +16.23%
Jun-11-24 01:00AM	Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 (GlobeNewswire) +13.41%
Jun-01-24 08:00AM	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 (GlobeNewswire)
May-16-24 04:00PM	Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program (GlobeNewswire)
Apr-29-24 11:00AM	Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action (GlobeNewswire)
Apr-19-24 11:12AM	Life Science Cares Launches in Switzerland (GlobeNewswire) -11.23%
Apr-17-24 11:12AM	Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting (GlobeNewswire)
Mar-26-24 09:26AM	Molecular Partners Publishes Invitation to Annual General Meeting 2024 (GlobeNewswire)
Mar-14-24 04:00PM	Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023 (GlobeNewswire)
Mar-01-24 04:00PM	Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations (GlobeNewswire)
Jan-07-24 04:00PM	Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-24 04:00PM	Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies (GlobeNewswire) +11.79%
Dec-14-23 01:00AM	Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences (GlobeNewswire) +7.41%
Dec-10-23 12:00PM	Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting (GlobeNewswire)
Nov-14-23 01:00AM	Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) (GlobeNewswire)
Nov-03-23 12:00PM	Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting (GlobeNewswire) +10.53%
Nov-02-23 02:00AM	Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) +14.52%
Nov-01-23 02:00AM	Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit (GlobeNewswire)
Oct-26-23 04:00PM	Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio (GlobeNewswire) +5.32%
Sep-13-23 01:00AM	Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting (GlobeNewswire) -5.41%
Aug-24-23 04:00PM	Molecular Partners Reports H1 2023 Corporate Highlights and Financials (GlobeNewswire)
Jul-13-23 08:06AM	Owning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN), (Simply Wall St.)
Jun-27-23 01:00AM	Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023 (GlobeNewswire)
Jun-19-23 12:00PM	Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit (GlobeNewswire)
Jun-02-23 08:59AM	Companies Like Molecular Partners (VTX:MOLN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:01PM	Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-16-23 04:00PM	Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference (GlobeNewswire) -5.55%
May-13-23 02:00AM	Getting In Cheap On Molecular Partners AG (VTX:MOLN) Is Unlikely (Simply Wall St.)
May-11-23 04:00PM	Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy (GlobeNewswire) +5.75%
Apr-18-23 01:44AM	Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 79% over the last five years (Simply Wall St.) -7.09%
Apr-14-23 01:00AM	Molecular Partners to Present Additional Preclinical Data Supporting the Companys Radio DARPin Therapy Platform at AACR (GlobeNewswire)
Apr-04-23 11:44AM	Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting (GlobeNewswire)
Mar-13-23 09:30AM	Molecular Partners Publishes Invitation to Annual General Meeting 2023 (GlobeNewswire) +9.04%
12:22AM	Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript (Insider Monkey)

Show Previous News

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Co-FounderDr. Patrick Amstutz Ph.D.

Co-FounderDr. Michael Tobias Stumpp Ph.D.

Senior VP of Finance & Member of Management BoardMr. Robert Hendriks

COO & Member of Management BoardMr. Alexander Zurcher

Executive VP of People & Community and Member of Management BoardMs. Renate Gloggner

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Molecular Partners AG ADR

Upgrade your Finviz experience